Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.86 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.86 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | PKM | P14618 | 1/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.86 |
| ▸ | THPO | P40225 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | ESR1 | P03372 | 1/20 | 0.86 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032 | 1.00 | CHRM2 (0.86) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Propane SCHEMBL16496189 | 0.99 | CHRM2 (0.85) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Esoxybutynin SCHEMBL290373 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Aroxybutynin SCHEMBL25880 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL2992 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL1560964 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL25751 | 0.92 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL8019436 | 0.92 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL19816026 | 0.92 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL7557853 | 0.92 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007072503-A2 | COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS | PANACEA BIOTEC LTD. (IN) | 2007-06-28 | — | — | WO | claimed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| EP-1476146-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | VERSI EBRAHIM (US) | 2003-10-09 | — | — | US | claimed |
| WO-2003070233-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| CN-104370760-A | Method for simulated moving bed chromatographic resolution of oxybutynin chloride enantiomers | JIANGSU HANBON SCI & TECH CO | 2015-02-25 | — | — | CN | disclosed |
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1804778-A1 | USE OF A BETA-3 AGONIST FOR TREATING COMPLAINTS OF THE PROSTATE AND THE LOWER UROGENITAL TRACT | Boehringer Ingelheim International GmbH (DE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007036543-A1 | BETA-3-AGONIST USE FOR TREATING KIDNEY AND BLADDER TROUBLES OF A PATIENT WITH SPINAL CORD DAMAGES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| EP-1769792-A1 | Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006042679-A1 | USE OF A BETA-3 AGONIST FOR TREATING COMPLAINTS OF THE PROSTATE AND THE LOWER UROGENITAL TRACT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1567149-A2 | PHARMACEUTICAL COMPOSITION COMPRISING BETA-3-ADRENOCEPTOR AGONISTS AND ANTIMUSCARINIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004047838-A2 | PHARMACEUTICAL COMPOSITION COMPRISING BETA-3-ADRENOCEPTOR AGONISTS AND ANTIMUSCARINIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | ADRB3, ADRB2, ADRB1 | CHRM2 17/4885CHRM1 33/4885CHRM4 29/4885 |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | CHRM2 93/4885CHRM1 199/4885CHRM4 148/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | CHRM2 45/4885CHRM1 68/4885CHRM4 85/4885 |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | PTGS2, PTGES2, PTGS1 | CHRM2 7/4885CHRM1 26/4885CHRM4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.